Elevance Health (ELV) Stock News Today: ACA Subsidy Deadline Looms, Fitch Affirms A- Rating, and Analysts See Modest Upside (Dec. 12, 2025)
Elevance Health (NYSE: ELV) is stabilizing near the $360 level after a sharp rebound, while Washington’s failure to extend ACA subsidies raises new 2026 uncertainty. Here’s the latest news, credit outlook, analyst forecasts, and technical setup as of December 12,